We are always looking for interesting early-stage pharmaceutical assets that we can finance to proof-of-concept in a capital efficient fashion with clear equity plans for all parties. We are also interested in funding late-stage biotech, platform technology or medical devices, mainly in Europe, North America including Canada and Asia.